Alcon Drags Down Novartis’s Emerging Markets Performance
This article was originally published in PharmAsia News
Novartis's performance in emerging markets slowed in the third quarter, due mainly to a slowdown in Asia and the sluggish results of Alcon, which was hit by weaker surgical equipment sales in the sector. Alcon is aiming to turn things around with revitalized leadership and a growth acceleration plan.
Register for our free email digests: